Gasdermin D Expression in Generalized Vitiligo Patients After Narrow-band Ultraviolet B Therapy

NCT06546059 | Not Yet Recruiting

• 1 other identifier: SVU-MED-,4-24,7,871
• Study Type: interventional
• Target: 40
• Locations: 0 countries
• Sites: N/A

Brief Summary

The aim of this study is to:

1. 1.Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls.
2. 2.Evaluation expression of tissue Gasdermin D using immunehistochemstry techniques in patients with generalized vitiligo after narrow band ultraviolet B therapy.
3. 3.Determine whether there is a relationship between Gasdermin D levels and disease duration and involved body surface area (VISA) in vitiligo patients.

Conditions

Vitiligo, Generalized

Outcome Measures

Primary Outcomes (1)

• Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls.

  1- Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls.techniques in patients with generalized vitiligo and compare it with healthy controls.

  three months

Secondary Outcomes (2)

• 2- Evaluation expression of tissue Gasdermin D using immunehistochemstry techniques in patients with generalized vitiligo after narrow band ultraviolet B therapy.

  three months

• 3- Determine whether there is a correlation between tissue immunehistochemstry Gasdermin D levels and disease duration and involved body surface area (VISA) in vitiligo patients.

  three months

Study Arms (1)

one group

OTHER

Device: narrow band ultraviolet-B

Interventions

narrow band ultraviolet-B DEVICE

vitiligo patients will recevie twice sessions per week

one group

Eligibility Criteria

• Age: 10 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with stable vitiligo of 6 months duration,
• Both sex and ages(10-75)

You may not qualify if:

• pregnancy,
• lactation,
• patients under or previous phototherapy,
• patients on other immunosuppressives,
• patients receiving topical or systemic therapy like antioxidants and vitamins were kept off treatment for 2 weeks prior to recruitment into the study.

Sponsors & Collaborators

• South Valley University: lead

MeSH Terms

Conditions

Vitiligo

Condition Hierarchy (Ancestors)

Hypopigmentation; Pigmentation Disorders; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Soheir Abdel-Hamid, MD

CONTACT

01066877343; soher.abdel-hamid@med.svu.edu.eg

Basma Tito Abd Elhameed, MD

CONTACT

01020304210; Basma.tito@med.svu.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Soheir Abdel-Hamid, principle investigator

Study Record Dates

• First Submitted: August 5, 2024
• First Posted: August 9, 2024
• Study Start: August 1, 2024
• Primary Completion: October 1, 2024
• Study Completion: November 1, 2024
• Last Updated: August 9, 2024

Record last verified: 2024-08